251 related articles for article (PubMed ID: 23724067)
1. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Stypula-Cyrus Y; Damania D; Kunte DP; Cruz MD; Subramanian H; Roy HK; Backman V
PLoS One; 2013; 8(5):e64600. PubMed ID: 23724067
[TBL] [Abstract][Full Text] [Related]
2. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
4. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
5. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Ye C; Han K; Lei J; Zeng K; Zeng S; Ju H; Yu L
Br J Pharmacol; 2018 Nov; 175(22):4209-4217. PubMed ID: 30076612
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn's Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets.
Lewis A; Humphreys DT; Pan-Castillo B; Berti G; Felice C; Gordon H; Gadhok R; Nijhuis A; Mehta S S; Eleid L; Iqbal S; Armuzzi A; Minicozzi A; Giannoulatou E; ChinAleong J; Feakins R; Sagi-Kiss V; Barisic D; Koufaki MI; Bundy JG; Lindsay JO; Silver A
J Crohns Colitis; 2024 Jun; 18(6):895-907. PubMed ID: 38069679
[TBL] [Abstract][Full Text] [Related]
8. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
Ashburner BP; Westerheide SD; Baldwin AS
Mol Cell Biol; 2001 Oct; 21(20):7065-77. PubMed ID: 11564889
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
10. Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3.
Leng Y; Wang J; Wang Z; Liao HM; Wei M; Leeds P; Chuang DM
Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 27207921
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Raghunathan S; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
15. Correlating colorectal cancer risk with field carcinogenesis progression using partial wave spectroscopic microscopy.
Gladstein S; Damania D; Almassalha LM; Smith LT; Gupta V; Subramanian H; Rex DK; Roy HK; Backman V
Cancer Med; 2018 May; 7(5):2109-2120. PubMed ID: 29573208
[TBL] [Abstract][Full Text] [Related]
16. Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
Kim JH; Moon SH; No M; Kim JJ; Choi EJ; Cho BJ; Kim JS; Kim IH; Kim IA
Cancer Res Treat; 2016 Jul; 48(3):1130-40. PubMed ID: 26582395
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
Ganai SA; Kalladi SM; Mahadevan V
J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.
Yamaguchi K; Lantowski A; Dannenberg AJ; Subbaramaiah K
J Biol Chem; 2005 Sep; 280(38):32569-77. PubMed ID: 15994313
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic Interactions between the Glucocorticoid Receptor and HDAC2 Regulate Osteocalcin Expression in VPA-Treated MSCs.
La Noce M; Mele L; Laino L; Iolascon G; Pieretti G; Papaccio G; Desiderio V; Tirino V; Paino F
Cells; 2019 Mar; 8(3):. PubMed ID: 30841579
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors dysregulate neural stem cell activity in the postnatal mouse brain.
Foti SB; Chou A; Moll AD; Roskams AJ
Int J Dev Neurosci; 2013 Oct; 31(6):434-47. PubMed ID: 23542004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
